This is a guest post from RoosterBio, written by Jon Rowley. RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation.
We blogged several months ago about bottlenecks in the bioprocessing of Mesenchymal Stem Cells that are impeding their clinical translation. While the development of robust and scalable manufacturing methods, reduced cost of goods, and implementation of solid Quality Systems are all necessary for increased clinical use of MSCs, there are also current misconceptions surrounding MSCs, rooted in decades-old science, that are holding the field back. [Read more…]